Abstract
Purpose
This study analyzed the current approaches for rectal cancer treatment in elderly patients.
Methods
We retrospectively studied 240 rectal cancer patients who had undergone radiotherapy from 2000 to 2008. The ages of the patients ranged from 65 and 75 years (group A, n = 127) and older than 75 years (group B, n = 113). The distribution of the Charlson comorbidity index was similar between the two groups, but the ECOG performance status (PS) differed between the groups (66 % of the patients of group A were PS 0, and 40 % were PS 0 in group B (p < 0.0001)). The tumor stages were comparable between groups.
Results
The median age of the patients was 74.3 years (range 65–90.6). Treatment was discussed during a multidisciplinary cancer team meeting before treatment for 55 % of the cases in group A and 73 % of the cases in group B (p < 0.001), and treatment proposals were in accordance with guidelines in 96 % of the cases in group A and 76 % of the cases in group B (p < 0.001). Group B patients received slightly less concurrent chemotherapy (35 vs. 30 % for group A; p = 0.54), more hypofractionated radiotherapy (41 vs. 54 % for group A; p = 0.064), less surgery (92 vs. 80 % for group A; p = 0.014), and less adjuvant chemotherapy (34 vs. 10 % for group A; p < 0.001). Finally, 80 % of the patients in group A and 60 % of the patients in group B received treatment in accordance with guidelines (p = 0.007) and in the logistic regression model. Non-metastatic patients who were aged below 75 years were predicted for conformal management (HR = 0.323; 95 % CI = 0.152–0.684) irrespective of their performance status, comorbidity, or disease stage.
Conclusions
Treatment proposals and administered therapy differed according to age.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Vercelli M, Capocaccia R, Quaglia A, Casella C, Puppo A, Coebergh JW (2000) Relative survival in elderly European cancer patients: evidence for health care inequalities. The Eurocare working group. Crit Rev Oncol Hematol 35:161–179
Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME (2006) The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145:646–653
Bouvier AM, Launoy G, Lepage C, Faivre J (2005) Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther 22:233–241
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN (2003) Ctcae v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181
Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5:224–237
Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389
Yee KW, Pater JL, Pho L, Zee B, Siu LL (2003) Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J Clin Oncol 21:1618–1623
Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23:3112–3124
Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M (2007) Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg 246:215–221
Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D, Mion M, Choudat L, Sobhani I, Mentre F, Soule JC (2009) Half of elderly patients routinely treated for colorectal cancer receive a substandard treatment. Crit Rev Oncol Hematol 71:249–257
Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S (2005) Comorbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 92:615–623
Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB (2001) Who gets adjuvant treatment for stage ii and iii rectal cancer? Insight from surveillance, epidemiology, and end results–Medicare. J Clin Oncol 19:3712–3718
(1997). Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med 336: 980–987.
M Fonck, JP Gekiere, C Blanc-Bisson, I Bourdel-Marchasson (2008) [state of nutrition and cancer in the elderly]. Bulletin du Cancer. 95 FMC Onco, F116-120
Kurtz J, Heitz D, Kurtz-Illig V, Dufour P (2009) Geriatric oncology: How far have we gone and what are the next steps? Oncology 77:147–156
Kurtz JE, Heitz D, Serra S, Brigand C, Juif V, Podelski V, Meyer P, Litique V, Bergerat JP, Rohr S (2010) Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution. Crit Rev Oncol Hematol 74:211–217
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guillerme, F., Clavier, J.B., Nehme-Schuster, H. et al. Age impacts the pattern of care for elderly patients with rectal cancer. Int J Colorectal Dis 29, 157–163 (2014). https://doi.org/10.1007/s00384-013-1778-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-013-1778-6